Skip to main content
. 2019 May 6;21(6):602–614. doi: 10.1016/j.neo.2019.03.008

Figure 1.

Figure 1

ALDH2 repression is associated with poor prognosis in human lung adenocarcinoma.

A. The mRNA expression of ALDH2 across all tumor samples and paired normal tissues in the Gene Expression Profiling Interactive Analysis (GEPIA) dataset. The histogram represents the median expression of ALDH2 mRNA in tumor and normal tissues. LUAD (lung adenocarcinoma) and LUSC (lung squamous cell carcinoma) were marked in red. B. Q-PCR analysis of ALDH2 in tumors and adjacent normal tissues of 16 lung adenocarcinoma patients. C. The overall survival (%) curves of lung adenocarcinoma patients with low or high ALDH2 expression. mRNA data was obtained from the Cancer Genome Atlas (TCGA) dataset. According to the mRNA level of ALDH2, patients are classified as ALDH2 high expression group (n = 200) and ALDH2 low expression group (n = 200). log-rank test p value = .0318. D. The overall survival (%) curves of lung adenocarcinoma patients with low or high ALDH2 expression from The Human Protein Atlas (THPA) dataset. E. Analysis of ALDH2 mRNA expression in lung adenocarcinoma tissues with different pathological stages in University of California Santa Cruz (UCSC) Xena dataset. t Test P = .0172 ("Stage I" vs. "Stage IV"); t test P = .0168 ("Stage I vs. "Stage II"); t Test P = .0377 ("Stage I" vs. "Stage III") *P < .05.